Dataset related to article "Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells"
Authors/Creators
- 1. Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy AND Department of Pharmaceutical Sciences, University of Pavia, Pavia, Italy
- 2. Humanitas Clinical and Research Center – IRCCS -, via Manzoni 56, 20089 Rozzano (Mi) - Italy
- 3. Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
- 4. Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy.
- 5. Humanitas Clinical and Research Center – IRCCS -, via Manzoni 56, 20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy
- 6. Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, Vesalius Research Center, VIB, Leuven, Belgium.
- 7. Department of Medicine, Section of Immunology, University of Verona, Verona, Italy.
- 8. Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy. AND Tumor and Microenvironment Histopathology Unit, the FIRC Institute of Molecular Medicine (IFOM), Milan, Italy.
- 9. Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy
Description
Cancer induces alteration of hematopoiesis to fuel disease progression. We report that in tumor-bearing mice the macrophage colony-stimulating factor elevates the myeloid cell levels of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD salvage pathway, which acts as negative regulator of the CXCR4 retention axis of hematopoietic cells in the bone marrow. NAMPT inhibits CXCR4 through a NAD/Sirtuin 1-mediated inactivation of HIF1α-driven CXCR4 gene transcription, leading to mobilization of immature myeloid-derived suppressor cells (MDSC) and enhancing their production of suppressive nitric oxide. Pharmacologic inhibition or myeloid-specific ablation of NAMPT prevented MDSC mobilization, reactivated specific antitumor immunity, and enhanced the antitumor activity of immune checkpoint inhibitors. Our findings identify NAMPT as a metabolic gate of MDSC precursor function, providing new opportunities to reverse tumor immunosuppression and to restore clinical efficacy of immunotherapy in patients with cancer. SIGNIFICANCE: These findings identify NAMPT as a metabolic gate of MDSC precursor function, providing new opportunities to reverse tumor immunosuppression and to restore clinical efficacy of immunotherapy in cancer patients.
Files
30777853_Nicotinamide Phosphoribosyltransferase Acts.zip
Additional details
Related works
- Is supplement to
- 30777853 (PMID)
- 10.1158/0008-5472.CAN-18-1544 (DOI)